HomeCompareCSPHF vs MO

CSPHF vs MO: Dividend Comparison 2026

CSPHF yields 198.02% · MO yields 9.11%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSPHF wins by $112.67M in total portfolio value
10 years
CSPHF
CSPHF
● Live price
198.02%
Share price
$1.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112.70M
Annual income
$56,534,499.65
Full CSPHF calculator →
MO
Altria Group Inc.
● Live price
9.11%
Share price
$44.80
Annual div
$4.08
5Y div CAGR
4.3%
Payout ratio
78%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.7K
Annual income
$4,052.72
Full MO calculator →

Portfolio growth — CSPHF vs MO

📍 CSPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSPHFMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSPHF + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSPHF pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSPHF
Annual income on $10K today (after 15% tax)
$16,831.68/yr
After 10yr DRIP, annual income (after tax)
$48,054,324.70/yr
MO
Annual income on $10K today (after 15% tax)
$774.11/yr
After 10yr DRIP, annual income (after tax)
$3,444.81/yr
At 15% tax rate, CSPHF beats the other by $48,050,879.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSPHF + MO for your $10,000?

CSPHF: 50%MO: 50%
100% MO50/50100% CSPHF
Portfolio after 10yr
$56.36M
Annual income
$28,269,276.18/yr
Blended yield
50.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

CSPHF
No analyst data
Altman Z
9.2
Piotroski
2/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
+36.7% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSPHF buys
0
MO buys
0
No recent congressional trades found for CSPHF or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSPHFMO
Forward yield198.02%9.11%
Annual dividend / share$2.00$4.08
Payout ratio50%78%
1-year div growth0%4.1%
5-year div CAGR0%4.3%
Portfolio after 10y$112.70M$27.7K
Annual income after 10y$56,534,499.65$4,052.72
Total dividends collected$106.15M$20.9K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CSPHF vs MO ($10,000, DRIP)

YearCSPHF PortfolioCSPHF Income/yrMO PortfolioMO Income/yrGap
1← crossover$30,502$19,801.98$10,740$949.88+$19.8KCSPHF
2$89,086$56,448.56$11,601$1,086.84+$77.5KCSPHF
3$249,403$154,080.96$12,608$1,250.75+$236.8KCSPHF
4$670,003$403,142.26$13,792$1,448.20+$656.2KCSPHF
5$1,729,066$1,012,162.66$15,190$1,687.69+$1.71MCSPHF
6$4,291,289$2,441,188.37$16,851$1,980.28+$4.27MCSPHF
7$10,253,990$5,662,310.92$18,838$2,340.48+$10.24MCSPHF
8$23,616,660$12,644,890.45$21,230$2,787.44+$23.60MCSPHF
9$52,487,868$27,218,041.68$24,130$3,346.72+$52.46MCSPHF
10$112,696,518$56,534,499.65$27,676$4,052.72+$112.67MCSPHF

CSPHF vs MO: Complete Analysis 2026

CSPHFStock

CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.

Full CSPHF Calculator →

MOConsumer Staples

Altria is a Dividend King with 54+ consecutive years of dividend increases — one of the longest streaks in American corporate history. While cigarette volumes decline, pricing power and new product categories (oral nicotine pouches via NJOY) support cash flows. The near-9% yield is among the highest in the S&P 500.

Full MO Calculator →
📬

Get this CSPHF vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSPHF vs SCHDCSPHF vs JEPICSPHF vs OCSPHF vs KOCSPHF vs MAINCSPHF vs PMCSPHF vs BTICSPHF vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.